Inhibition of PI3K and SFK pathways induces apoptosis in PBMCs from patients with LGL leukemia. (A-B) Freshly isolated PBMCs from a representative patient with NK-LGL leukemia (A) or a patient with T-LGL leukemia (B) were treated with LY129004 (PI3K inhibitor) or PP2 (SFK inhibitor) at doses of 10, 25, or 50μM/L, respectively, and with the combination of both inhibitors at doses of 10 and 25μM/L concentrations for 24 or 48 hours, respectively. DMSO served as vehicle control. (C) PBMCs from 5 patients with T-LGL leukemia (patients 1-5), from 4 patients with NK-LGL leukemia (patients 6-9), and from 4 normal controls (NLs 10-13) were treated with LY129004 or SFK PP2 at a concentration of 25μM, or with the combination of LY and PP2 at 25μM for 24 hours. Apoptosis was determined by flow cytometry assay with annexin-V–FITC/7-amino-actinomycin D staining.